Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.
Blue Cross and Blue Shield of Montana (BCBSMT) may consider laser-assisted tympanostomy with insertion of a pressure-equalizing tube (PET) medically necessary in patients with chronic otitis media who meet criteria for conventional insertion of a PET.
BCBSMT considers laser-assisted myringotomy (without insertion of a PET) not medically necessary as a treatment of acute otitis media.
BCBSMT considers laser-assisted myringotomy (also called laser-assisted tympanic membrane fenestration or LTMF) experimental, investigational and unproven as an alternative to tympanostomy with PET insertion.
There are no specific CPT codes for laser-assisted tympanostomy and myringotomy. NOTE: There should be no additional reimbursement for any of these procedures performed as laser assisted.
A laser-assisted myringotomy (also called laser-assisted membrane fenestration or LTMF) is a unique procedure when it is considered an alternative to a conventional tympanostomy with tube insertion. Pressure-equalizing tubes (PETs) can provide aeration for 6–12 months, while the duration of laser- assisted myringotomies is not known, but will vary with the size of the fenestration spot. In addition, the minimal time of aeration leading to resolution of chronic otitis media, while also reducing the risk of recurrent disease, is not precisely known, and may be variable for different subgroups of patients. For example, children with upper airway obstruction caused by adenotonsillar hypertrophy may be incidentally found to have chronic otitis media; these patients may not require prolonged aeration. A controlled clinical trial among homogeneous groups of patients is required to resolve this issue. No such trial has been reported, and the published literature is dominated by case series.
Brodsky and colleagues reported on a case series of 54 patients (96 ears), aged 6 months to 23 years, who met criteria for insertion of a pressure-equalizing tube (PET) and underwent laser-assisted myringotomy. (1) These criteria included recurrent otitis media, chronic otitis media with effusion, or eustachian tube dysfunction. All patients had failed medical management. All procedures were performed in the office with the use of topical anesthesia. Pain was described as absent in 39%, tolerable in 30%, and severe in 30% immediately after the procedure. Within 5 minutes the pain was reported absent in 75%, tolerable in 22%, and severe in 5%. Ninety-two percent of parents were highly satisfied with the procedure as an alternative to PET insertion using general anesthesia. The average time of the procedure was 8.57 minutes. The authors concluded that office-based laser-assisted tympanostomy with PET insertion is possible in a broad range of patients. The same group of authors published a subsequent study that focused on the duration of patency of laser myringotomy in patients with acute otitis media or otitis media with effusion. (2) This outcome is critical to determine whether patency is maintained for an adequate period of time such that patients can forego insertion of PETs. The case series included 251 children (430 ears), in whom fenestration closure was evaluable in 201 ears. The spot size of the myringotomy was variable in the children (from 1.8 mm to 2.8 mm), and the authors also sought to evaluate the optimal size of the myringotomy fenestration. Increased duration of patency was accomplished with spot sizes of 2.4 and 2.6 mm compared with smaller spot sizes. The authors conclude that laser-assisted myringotomy provides intermediate duration fenestration, but that additional investigation is required to determine optimum spot size and duration of fenestration.
Sedlmaier and colleagues also examined the ventilation time associated with laser-assisted myringotomy in a case series of 81 children (159 ears) with chronic otitis media associated with adenoidal and/or tonsillar hypertrophy. (3) The spot size was approximately 2 mm in diameter. The mean closure time was 16.35 days. Otitis media recurred in 26.3% of the ears with mucous secretion and 13.5% of the ears with serous secretion. The authors conclude that laser-assisted myringotomy may be an alternative to ventilation tube placement in those with serous effusions.
Smaller case series have also suggested that laser-assisted myringotomy successfully aerates the middle ear in 46%–66% of patients for a period up to 3 months. (4-8) Due to the lack of controlled studies, laser-assisted myringotomy is considered investigational as an alternative to tympanostomy with PET insertion. However, it is recognized that there may be physician and patient acceptance for the laser procedure, based on the fact that it is an office-based procedure that only requires topical anesthesia.
Surgical aeration of the middle ear is indicated to relieve pressure acutely and to restore hearing. Symptoms suggestive of acute otitis media are ear pain, irritability, sleepiness in conjunction with bulging immobility of the tympanic membrane, erythema, loss of landmarks, and tympanic membrane (TM) exudate. Conventional treatment of acute otitis media includes antibiotics. Problematic patients are those who continue to be symptomatic despite antibiotic therapy. Many times these patients may receive several courses of empirically chosen antibiotics. Laser-assisted myringotomy has been proposed as a technique to simultaneously provide an accurate diagnosis with the culture results used to select an appropriate antibiotic. However, this unique role of myringotomy has not been the subject of a peer-reviewed article and it is not known whether the use of the laser procedure provides any advantage compared to the conventional office-based procedure using a myringotomy knife.
Cotter and Kosko conducted a retrospective review of 47 children with otitis media who underwent laser-assisted myringotomy. (9) A total of 57.4% of procedures were considered treatment failures due to recurrence or persistence of disease. The authors suggest that any use of the OtoLam device should include discussion of the high likelihood of subsequent ventilation tube insertion.
A European study reported on a randomized study of 30 pediatric patients with otitis media with effusion comparing laser myringotomy to tympanostomy with PET. (10) Middle ear ventilation was maintained for 3.5 months following the laser technique and for 6.3 months for placement of tubes; this difference was statistically significant. The authors note that further study is needed to clarify the role of laser myringotomy.
The indications for PET tubes continue to evolve. Paradise and colleagues recently reported long-term results of a randomized study of immediate versus delayed PET placement in infants with persistent middle-ear effusions. (11) This study concluded that in otherwise healthy young children who have persistent middle-ear effusion, prompt insertion of tympanostomy tubes does not improve developmental outcomes up to 9 to 11 years of age.
A search of peer reviewed literature through March 2013 identified no new clinical trial publications or any additional information that would change the coverage position of this medical policy.
Disclaimer for coding information on Medical Policies
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.
The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.
Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.